Companies
- Companies
- Company details
BC Cancer Agency
Out-licensing
ChemoPath 5-FU™: A Method to Identify the Cancer Patients who will Respond to 5-fluorouracil Treatment More
Cholicure™ Compounds for the Treatment of Cholestasis More
Clinical Development of Irinophore C™ for the Treatment of Colon Cancer More
CytSpot™ to Increase the Reproducibility and Throughput of Cytology based Genomic Screening Techniques More
DermID™: A Novel Detection Device for the Diagnosis of Melanoma More
Development of a Novel Ultrasound Imaging Technique for Prostate Cancer More
Identification of a Podocalyxin: A Novel Breast Cancer Marker for Detection and Diagnosis of Breast Malignancies More
ProstaChip™: A cDNA Microarray for the Diagnosis of Prostate Cancer More
Raman Based Cancer Detection: Improved Cancer Detection Sensitivity and Specificity More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 43 pages - $500
Jan 2011 - 4 pages - $500
Nov 2009 - 160 pages - $2,265
Aug 2011 - 8 pages - $75
Aug 2011 - 7 pages - $75
Jan 2012 - 15 pages - $250
Nov 2011 - 6 pages - $75
Nov 2011 - 7 pages - $75
Nov 2011 - 6 pages - $75
Nov 2011 - 6 pages - $75
Contact details
Patrick Rebstein
Head office
BC Cancer Agency
Technology Development Office 675 West 10th Avenue
Vancouver
V5Z 1L3
British Columbia (Canada)
Technology Development Office 675 West 10th Avenue
Vancouver
V5Z 1L3
British Columbia (Canada)
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us